Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Massimo Breccia, MD, Roberto Latagliata, MD, Laura Cannella, MD, Ida Carmosino, MD, Enrico Gottardi, Daniela Cilloni, MD, Marco Vignetti, MD, Michelina Santopietro, MD, Marco Mancini, MD, Giuliana Alimena, MD

Blood (2009) 114 (22): 1777.

https://doi.org/10.1182/blood.V114.22.1777.1777

Published: 2009

Journal Articles

Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.

Massimo Breccia, MD, Fabio Stagno, MD, Roberto Latagliata, MD, Paolo Vigneri, MD, Laura Cannella, MD, Ida Carmosino, MD, Vittorio Del Fabro, MD, Francesco Di Raimondo, MD, Giuliana Alimena, MD

Blood (2009) 114 (22): 3302.

https://doi.org/10.1182/blood.V114.22.3302.3302

Published: 2009

Journal Articles

Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.

Roberto Latagliata, MD, Angela Rago, MD, Antonio Spadea, MD, Cristina Santoro, MD, Ida Carmosino, MD, Massimo Breccia, MD, Laura Napoleone, MD, Angelo Fama, MD, Francesca Biondo, MD, Paola Volpicelli, MD, Maria Concetta Petti, PhD, Giuliana Alimena, PhD, Maria Gabriella Mazzucconi, PhD

Blood (2007) 110 (11): 4636.

https://doi.org/10.1182/blood.V110.11.4636.4636

Published: 2007

Journal Articles

Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.

Esther N. Oliva, MD, Margherita Comis, MD, Pasquale Iacopino, MD, Mariella Cuzzola, BSc, Roberto Latagliata, MD, Marco Danova, MD, Bianca Rovati, MD, Giovanni Spampinato, Giuliana Alimena, MD, Ida Carmosino, MD, Massimo Breccia, MD, Francesco Nobile, MD

Blood (2007) 110 (11): 4609.

https://doi.org/10.1182/blood.V110.11.4609.4609

Published: 2007

Journal Articles

JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.

Angela Rago, MD, Chiara Marzano, MD, Corrado Mammì, MD, Carmelo Laganà, MD, Angelo Fama, MD, Luisa Bizzoni, MD, Gabriella Tomei, MD, Stefania Trasarti, MD, Francesca Gioisa, MD, Massimo Breccia, MD, Ida Carmosino, MD, Roberto Latagliata, MD, Giuliana Alimena, MD, Robert Foa, MD, Oliviero Riggio, MD, Agostino Tafuri, MD

Blood (2007) 110 (11): 4652.

https://doi.org/10.1182/blood.V110.11.4652.4652

Published: 2007

Journal Articles

Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.

Esther N. Oliva, MD, Roberto Latagliata, MD, Marco Danova, MD, Iolanda Vincelli, MD, Bianca Rovati, MD, Francesca Ronco, MD, Ida Carmosino, MD, Giorgina Specchia, MD, Massimo Breccia, MD, Stefana Impera, MD, Imma Attolico, MD, Francesco Nobile, MD

Blood (2006) 108 (11): 2667.

https://doi.org/10.1182/blood.V108.11.2667.2667

Published: 2006

Journal Articles

Quality of Life in Elderly Patients with Acute Myeloid Leukemia.

Esther N. Oliva, MD, Roberto Latagliata, MD, Iolanda Vincelli, MD, Giorgina Specchia, MD, Francesca Ronco, MD, Vincenzo Liso, MD, Stefana Impera, MD, Caterina Alati, MD, Alessandra Quota, MD, Giuliana Alimena, MD, Massimo Breccia, MD, Ida Carmosino, MD, Francesco Fortugno, MD, Francesco Nobile, MD

Blood (2006) 108 (11): 3320.

https://doi.org/10.1182/blood.V108.11.3320.3320

Published: 2006

Journal Articles

Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.

Iolanda Vincelli, MD, Esther N. Oliva, MD, Roberto Latagliata, MD, Giorgina Specchia, MD, Giuliana Alimena, MD, Massimo Breccia, MD, Caterina Alati, MD, Ida Carmosino, MD, Grazia Iaria, MD, Antonio Marino, MD, Natale Ranieri, MD, Vincenzo Liso, MD, Francesca Ronco, MD, Bruno Martino, MD, Francesco Nobile, MD

Blood (2006) 108 (11): 3595.

https://doi.org/10.1182/blood.V108.11.3595.3595

Published: 2006

Journal Articles

Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.

Giuliana Alimena, MD, Massimo Breccia, MD, Luigia Luciano, MD, Fabrizio Quarantelli, PhD, Daniela Diverio, PhD, Barbara Izzo, MD, Biagio De Angelis, Marco Mancini, MD, Roberto Latagliata, MD, Ida Carmosino, MD, Mauro Nanni, PhD, Bruno Rotoli, MD, Franco Mandelli, MD, Fabrizio Pane, MD

Blood (2006) 108 (11): 2158.

https://doi.org/10.1182/blood.V108.11.2158.2158

Published: 2006

Journal Articles

Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.

Massimo Breccia, MD, Roberto Latagliata, MD, Ida Carmosino, MD, Eleonora Russo, MD, Mariella D’Andrea, MD, Erica Finolezzi, MD, Nicol Iorio, MD, Cinzia Fazio, MD, Giuseppe Avvisati, PhD, Maria Concetta Petti, PhD, Francesco Lo-Coco, PhD, Franco Mandelli, PhD

Blood (2005) 106 (11): 887.

https://doi.org/10.1182/blood.V106.11.887.887

Published: 2005

Journal Articles

Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.

Roberto Latagliata, MD, Massimo Breccia, MD, Ida Carmosino, MD, Chiara Sarlo, MD, Rosa De Cuia, MD, Marco Mancini, MD, Francesca Biondo, MD, Eleonora Russo, MD, Annalisa De Vellis, MD, Daniela Diverio, MD, Franco Mandelli, PhD, Giuliana Alimena, PhD

Blood (2004) 104 (11): 4693.

https://doi.org/10.1182/blood.V104.11.4693.4693

Published: 2004

NARROW

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.

Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.

Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.

JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.

Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.

Quality of Life in Elderly Patients with Acute Myeloid Leukemia.

Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.

Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.

Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.

Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only